David A. Siegel Biomarin Pharmaceutical Inc Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Two Sigma Advisers, LP holds 181,314 shares of BMRN stock, worth $11.5 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

181,314

Previous 231,914 21.82%

Holding current value

$11.5 Million

Previous $19.1 Million 33.25%

% of portfolio

0.03%

Previous 0.04%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$69.02 - $93.84 $3.49 Million - $4.75 Million	-50,600 Reduced 21.82%	181,314 $12.7 Million
Q2 2024 Aug 14, 2024	SELL	$74.43 - $92.22 $23.3 Million - $28.9 Million	-313,100 Reduced 57.45%	231,914 $19.1 Million
Q1 2024 May 15, 2024	BUY	$83.81 - $99.0 $17.6 Million - $20.8 Million	209,800 Added 62.59%	545,014 $47.6 Million
Q4 2023 Feb 14, 2024	SELL	$76.22 - $98.51 $18.2 Million - $23.5 Million	-238,300 Reduced 41.55%	335,214 $32.3 Million
Q3 2023 Nov 14, 2023	SELL	$85.07 - $94.48 $15 Million - $16.7 Million	-176,600 Reduced 23.54%	573,514 $50.7 Million
Q2 2023 Aug 14, 2023	SELL	$86.68 - $100.3 $22.5 Million - $26 Million	-259,500 Reduced 25.7%	750,114 $65 Million
Q1 2023 May 15, 2023	BUY	$87.74 - $117.27 $23.9 Million - $32 Million	272,700 Added 37.01%	1,009,614 $98.2 Million
Q4 2022 Feb 14, 2023	BUY	$80.93 - $108.63 $27.6 Million - $37 Million	340,800 Added 86.04%	736,914 $76.3 Million
Q3 2022 Nov 14, 2022	BUY	$82.16 - $96.94 $11.4 Million - $13.5 Million	139,200 Added 54.18%	396,114 $33.6 Million
Q3 2022 Nov 14, 2022	BUY	$82.16 - $96.94 $11.4 Million - $13.5 Million	139,200 Added 54.18%	396,114 $33.6 Million
Q2 2022 Aug 15, 2022	BUY	$71.48 - $86.85 $1.99 Million - $2.41 Million	27,800 Added 12.13%	256,914 $21.3 Million
Q1 2022 May 16, 2022	BUY	$74.28 - $92.69 $8.77 Million - $10.9 Million	118,100 Added 106.38%	229,114 $17.7 Million
Q4 2021 Feb 14, 2022	BUY	$71.72 - $91.47 $3.7 Million - $4.72 Million	51,600 Added 86.85%	111,014 $9.81 Million
Q3 2021 Nov 15, 2021	SELL	$74.77 - $85.47 $11.1 Million - $12.6 Million	-147,800 Reduced 71.33%	59,414 $4.59 Million
Q2 2021 Aug 16, 2021	BUY	$75.51 - $84.79 $15.6 Million - $17.6 Million	207,214 New	207,214 $17.3 Million
Q2 2020 Aug 14, 2020	SELL	$79.55 - $124.22 $6.53 Million - $10.2 Million	-82,104 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$71.37 - $96.85 $32.6 Million - $44.2 Million	-456,300 Reduced 84.75%	82,104 $6.94 Million
Q4 2019 Feb 14, 2020	BUY	$64.27 - $86.37 $308,496 - $414,576	4,800 Added 0.9%	538,404 $45.5 Million
Q3 2019 Nov 14, 2019	BUY	$67.4 - $85.11 $15.5 Million - $19.5 Million	229,500 Added 75.47%	533,604 $36 Million
Q2 2019 Aug 14, 2019	BUY	$80.35 - $93.9 $15.2 Million - $17.8 Million	189,400 Added 165.12%	304,104 $26 Million
Q1 2019 May 15, 2019	BUY	$84.2 - $98.62 $3.6 Million - $4.21 Million	42,700 Added 59.3%	114,704 $10.2 Million
Q4 2018 Feb 14, 2019	SELL	$80.14 - $106.07 $1.67 Million - $2.22 Million	-20,900 Reduced 22.5%	72,004 $6.13 Million
Q3 2018 Nov 14, 2018	BUY	$93.92 - $105.72 $1.8 Million - $2.03 Million	19,200 Added 26.05%	92,904 $9.01 Million
Q2 2018 Aug 14, 2018	BUY	$76.01 - $99.03 $5.6 Million - $7.3 Million	73,704 New	73,704 $6.94 Million

Others Institutions Holding BMRN

# of Institutions

635

Shares Held

178M

Call Options Held

2.01M

Put Options Held

1.28M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $11.8B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account